Veterinary Archives, Vol. 81 No. 2, 2011.
Original scientific paper
Adjuvant activity of levamisole for experimental F18ac+ Escherichia coli oral vaccine against porcine post-weaning colibacillosis.
Frane Božić
; Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Zagreb, Zagreb, Croatia
Frane Banović
; Clinic of Internal Diseases, Faculty of Veterinary Medicine, University of Zagreb, Zagreb, Croatia
Jelena Šuran
; Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Zagreb, Zagreb, Croatia
Andreja Prevendar Crnić
; Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Zagreb, Zagreb, Croatia
Abstract
It has been suggested that the Escherichia coli strain expressing F18 fi mbriae possesses lower capability of stimulation of immune responses in weaned pigs than the F4+ E. coli strain. In order to overcome this problem, we used levamisole as a candidate mucosal adjuvant for an experimental F18ac+ E. coli oral vaccine. We hypothesized that levamisole may exert its adjuvant activity in weaned pigs vaccinated with experimental F18+ E. coli oral vaccine by triggering the immune effector sites of the gut-associated lymphoid tissue (GALT), such as the mesenteric lymph node (MLN). Therefore, flow cytometry was used to analyze CD25, SWC7, and SWC9 activation antigens expression on the surfaces of MLN and spleen T cells, B cells and macrophages, respectively, isolated from levamisole-primed F18ac+ non enterotoxigenic E. coli (ETEC)-vaccinated (N = 5) or sham-vaccinated (N = 5) challenge-inoculated weaned pigs. Our results have shown that levamisole synergizes experimental F18ac+ E. coli oral vaccine in stimulating activation of CD25+ T cells, SWC7+ B cells, and SWC9+ macrophages preferentially in the MLN of challenged weaned pigs.
Keywords
levamisole; cell-mediated immune response; weaned pigs; vaccination; colibacillosis
Hrčak ID:
67326
URI
Publication date:
26.4.2011.
Visits: 1.139 *